3 ms·

BPC-157, when injected, is almost always injected subcutaneously. In which case it's not "targeted" at all.

wholinator2 4y ago
Is that true? Genuinely asking. Because all of the "conventional wisdom" I've picked up is that ingesting it works great for stomach ailments like ulcers with a small amount of 'fixing' throughout the rest of the body. But if you sprained your knee, you're better off injecting it at the knee site than eating it. People and probable placebo seem to think injecting really targets it. Is subcutaneous injection really that untargeted? And does the highly interested patient have the background to know how to inject it properly, if there really is a way to target it?
- A_D_E_P_T 4y ago
  Yes. The paper "pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat" (Sikiric et al. 2010) examined BPC-157 orally and via IP injection -- there was very little difference between the two methods. And this was in an animal model where the MCL ligament, in the leg, was surgically transected. Further, consider insulin. It's typically administered as an aqueous solution injected subcutaneously, and it's absorbed quickly and systemically, with local effects in the near-zero range. It's possible to make an aqueous solution for SC injection that might have some degree of local efficacy, if it's injected near a target site. This, however, would involve tinkering with the PH of the solution to induce drug precipitation, post-injection, near the injection site. It's complicated, and not the sort of thing that gray market research chemists do.
  - GeoRandel 4y ago
    Would BPC-157 be something that could be packaged in a liposome? Everything I've read about liposomal supplements has pointed to it having superior absorption, distribution and bioavailability when compared to injection
    - A_D_E_P_T 4y ago
      Yeah, you can incorporate BPC-157 and other small peptides into liposomes. Liposomal delivery might even work for far larger peptides and proteins. For e.g., there has been quite a lot of research into liposomal insulin: https://pubmed.ncbi.nlm.nih.gov/2226109 https://pubmed.ncbi.nlm.nih.gov/2226109 and others. The thing about BPC-157 in particular is that it has, in principle, pretty good oral bioavailability, and it's not clear that it would benefit from liposomal delivery. You'd probably want to run a comparative analysis -- liposomal suspension vs. plain aqueous solution -- which would be expensive no matter how you go about it.
lolc 4y ago
My doctor uncle told me how people want targeted injection even though "the stuff will spread to the whole body anyway". He says "it makes them feel good so we do it that way."

Is that true? Genuinely asking. Because all of the "conventional wisdom" I've picked up is that ingesting it works great for stomach ailments like ulcers with a small amount of 'fixing' throughout the rest of the body. But if you sprained your knee, you're better off injecting it at the knee site than eating it. People and probable placebo seem to think injecting really targets it. Is subcutaneous injection really that untargeted? And does the highly interested patient have the background to know how to inject it properly, if there really is a way to target it?

A_D_E_P_T 4y ago
Yes. The paper "pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat" (Sikiric et al. 2010) examined BPC-157 orally and via IP injection -- there was very little difference between the two methods. And this was in an animal model where the MCL ligament, in the leg, was surgically transected. Further, consider insulin. It's typically administered as an aqueous solution injected subcutaneously, and it's absorbed quickly and systemically, with local effects in the near-zero range. It's possible to make an aqueous solution for SC injection that might have some degree of local efficacy, if it's injected near a target site. This, however, would involve tinkering with the PH of the solution to induce drug precipitation, post-injection, near the injection site. It's complicated, and not the sort of thing that gray market research chemists do.
- GeoRandel 4y ago
  Would BPC-157 be something that could be packaged in a liposome? Everything I've read about liposomal supplements has pointed to it having superior absorption, distribution and bioavailability when compared to injection
  - A_D_E_P_T 4y ago
    Yeah, you can incorporate BPC-157 and other small peptides into liposomes. Liposomal delivery might even work for far larger peptides and proteins. For e.g., there has been quite a lot of research into liposomal insulin: https://pubmed.ncbi.nlm.nih.gov/2226109 https://pubmed.ncbi.nlm.nih.gov/2226109 and others. The thing about BPC-157 in particular is that it has, in principle, pretty good oral bioavailability, and it's not clear that it would benefit from liposomal delivery. You'd probably want to run a comparative analysis -- liposomal suspension vs. plain aqueous solution -- which would be expensive no matter how you go about it.

lolc 4y ago

My doctor uncle told me how people want targeted injection even though "the stuff will spread to the whole body anyway". He says "it makes them feel good so we do it that way."